Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARLATEM
2023-510568-11-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab and temozolomide in brain neoplasm, glioma and Neuro-Oncological Malignancies, sponsored by Centre Léon Bérard. Primary endpoints: Dose-limiting toxicities and Objective response rate at 12 weeks. Planned start Aug 2025; status: authorised.
02
Drugs
tarlatamabtemozolomide
03
Conditions
brain neoplasmgliomaNeuro-Oncological Malignancies
Beyond the preview
Go deeper on 2023-510568-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510568-11-00.